Literature DB >> 12521210

Pulmonary alveolar proteinosis successfully treated with ambroxol.

Toshihiko Hashizume1.   

Abstract

A 79-year-old woman was admitted to hospital due to a four-month history of a cough and dyspnea on exertion. Chest CT scans revealed ground glass opacity with thickened interlobular septa in both lungs. Bronchoalveolar lavage fluid (BALF) had milky appearance and revealed large acellular eosinophilic amorphous bodies positively stained with periodic acid-Schiff (PAS). Autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) were present in sera and BALF from the patient. Ambroxol was started in a daily dose of 45 mg orally. Her oxygen saturation improved and abnormal shadows in CT scan disappeared 6 months after beginning the therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12521210     DOI: 10.2169/internalmedicine.41.1175

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  Rare lung disease II: pulmonary alveolar proteinosis.

Authors:  Stephen C Juvet; David Hwang; Thomas K Waddell; Gregory P Downey
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

2.  Marked improvement in autoimmune pulmonary alveolar proteinosis with severe hypoxemia in a patient treated with ambroxol: a case report.

Authors:  Nao Oda; Koji Tamai; Yujiro Suzuki; Harukazu Yoshimatsu; Hirofumi Matsuoka; Yusuke Matsumoto; Nobuhiko Okada
Journal:  J Med Case Rep       Date:  2015-05-06

Review 3.  Metabolic Functions of the Lung, Disorders and Associated Pathologies.

Authors:  Alcibey Alvarado; Isabel Arce
Journal:  J Clin Med Res       Date:  2016-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.